U088 What's New in Onychomycosis?
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
The epidemiology of onychomycosis is changing with an increase in the number of non-dermatophyte molds and mixed infections: an update will be presented. The newer methods of diagnosing onychomycosis will be compared and contrasted with the traditional methods. The expanding repertoire of newer orals, topicals and devices for onychomycosis will be discussed. The emergence of resistant organisms and management options will be highlighted. Strategies for sanitizing shoes and socks will be presented, along with prophylactic treatments to reduce recurrence. The session will be interactive with periodic questions to the audience and audience participation will be encouraged.
LEARNING OBJECTIVES
Understand the pros and cons of the traditional and newer methods for diagnosing onychomycosis
Appreciate why some patient demonstrate sub-optimal response to treatment and how to increase efficacy
Choose optimal treatment of non-dermatophyte molds and mixed infection onychomycosis
SCHEDULE
2:30 PM
What's New in the diagnosis of Onychomycosis
Jasmine Rana, MD, FAAD
2:45 PM
What's New in Pediatric Onychomycosis
Julie Mervak, MD, FAAD
3:00 PM
What's New in Non-dermatophyte Mold Onychomycosis
Bianca Maria Piraccini, MD, IFAAD
3:15 PM
What's New in the Management of Onychomycosis
Aditya K. Gupta, MD, PhD, FAAD
SPEAKERS
Aditya K. Gupta, MD, PhD, FAAD
Julie Mervak, MD, FAAD
Bianca Maria Piraccini, MD, IFAAD
Jasmine Rana, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Aditya K. Gupta, MD, PhD, FAAD
Bausch Health – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Emblation Limited – Investigator(Grants/Research Funding); Moberg Derma – Consultant(Fees); Ortho Dermatologics – Consultant(Fees);
Julie Mervak, MD, FAAD
No financial relationships exist with ineligible companies.
Bianca Maria Piraccini, MD, IFAAD
ISDIN – Consultant(Fees); L'Oréal France – Advisory Board(Fees); Pierre Fabre Dermo Cosmetique France – Advisory Board(Fees);
Jasmine Rana, MD, FAAD
No financial relationships exist with ineligible companies.